Autres langues Oncternal Therapeutics, Inc.

Actions

ONCT

US68236P2065

Temps Différé Nasdaq Autres places de cotation 17:46:58 14/05/2024			Varia. 5j.	Varia. 1 janv.
8,881 ^USD	+3,26 %		+4,23 %	-17,19 %

09/05	Transcript : Oncternal Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Oncternal Therapeutics, Inc. annonce ses résultats pour le quatrième trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Oncternal Therapeutics : Corporate Presentation, May 2024	11/05
Oncternal Therapeutics: Q1 Earnings Snapshot	09/05
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	09/05
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results	09/05
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results	02/05
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/05
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	15/03
Oncternal Therapeutics: Q4 Earnings Snapshot	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	07/03
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	29/02
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/02
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	01/02
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics Announces Reverse Stock Split	04/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncternal Therapeutics, Inc.

Actions

ONCT

US68236P2065

Autres langues

Filtres